Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-16-081383

Chief Financial Officer acquired 4,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Goeltz II Robert C. · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2016-09-29 Exercise or conversion : show line 1 in the form +4,000 $4.47 $17,891 6,000 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2016-09-29 Exercise or conversion : show line 2 in the form Employee Stock Option (right to buy) −4,000 241,675 D
Loading xslF345X03/doc1.xml…